Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Haematologica
|
April 26, 2019
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Luciano Cascione, Andrea Rinaldi, Alessio Bruscaggin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
Alberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Blood
|
May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
Alberto J Arribas, Eleonora Cannas, Giulio Sartori, et al.
Haematologica
|
June 20, 2024
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers
Filippo Spriano, Giulio Sartori, Jacopo Sgrignani, et al.
Haematologica
|
August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia
Fary Diop, Riccardo Moia, Chiara Favini, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica
|
November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Haematologica
|
April 26, 2019
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Luciano Cascione, Andrea Rinaldi, Alessio Bruscaggin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Biorxiv : the Preprint Server for Biology
|
July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
Alberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Blood
|
May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
Alberto J Arribas, Eleonora Cannas, Giulio Sartori, et al.
Haematologica
|
June 20, 2024
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers
Filippo Spriano, Giulio Sartori, Jacopo Sgrignani, et al.
Haematologica
|
August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia
Fary Diop, Riccardo Moia, Chiara Favini, et al.
Page
of 6